Prognostic markers in core‐binding factor AML and improved survival with multiple consolidation cycles of intermediate‐/high‐dose cytarabine
- 1 May 2018
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 101 (2) , 174-184
Abstract
Objectives: Core‐binding factor acute myeloid leukaemia (CBF AML) defined by t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) has a favourable prognosis; however, 30%‐40% of patients still relapse after chemotherapy. We sought to evaluate the risk factors for relapse in a de novo CBF AML cohort.Patients/Materials/Methods: A retrospective review of patients from four Australian tertiary centres from 2001 to 2012, comprising 40 t(8;21) and 30 inv(16) AMLs.Results: Multivariate analysis identified age (P = .032) and white cell count (WCC)>40 (P = .025) as significant predictors for inferior OS and relapse, respectively. Relapse risk was higher in the inv(16) group vs the t(8;21) group (57% vs 18%, HR 4.31, 95% CI: 1.78‐10.42, P = .001). Induction therapy had no bearing on OS or relapse‐free survival (RFS); however, consolidation treatment with >3 cycles of intermediate‐/high‐dose cytarabine improved OS (P = .035) and RFS (P = .063). Five patients demonstrated post‐treatment stable q PCR positivity without relapse.Conclusions: >3 consolidation cycles of intermediate‐/high‐dose cytarabine improves patient outcomes Age and inv(16) CBF AML subtype are predictors of inferior OS and RFS, respectively. Stable low‐level MRD by qPCR does not predict relapse Similar OS in the inv(16) cohort compared to the t(8;21) cohort, despite a higher relapse rate, confirms salvageability of relapsed disease.Keywords
This publication has 25 references indexed in Scilit:
- Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trialHaematologica, 2015
- Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaBlood, 2013
- Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)Blood, 2013
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trialBlood, 2012
- Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinBlood, 2011
- Cytarabine Dose for Acute Myeloid LeukemiaNew England Journal of Medicine, 2011
- Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 StudyJournal of Clinical Oncology, 2010
- Age and acute myeloid leukemiaBlood, 2006
- Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)Leukemia, 2006
- Core-binding factors in haematopoiesis and leukaemiaNature Reviews Cancer, 2002